ProMIS director granted options on 16,500 shares

ProMIS Neurosciences Inc. director Madge K. Shafmaster reported two option awards that provide the right to buy common shares.

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. director Madge K. Shafmaster reported two option awards that provide the right to buy common shares. One grant covers 11,000 underlying common shares at an exercise price of $10.7700 per share and expires on May 20, 2036.

According to the filing, another grant covers 5,500 underlying common shares at the same $10.7700 exercise price and the same expiration date. One option vests in full on May 20, 2027, while the other vests 25% at grant with the remaining shares vesting ratably over thirty-six months, in each case subject to continued service on the Board.

Insider Trade Summary

Grant/Award: 16,500 shares

Grant/Award 2 txns

Insider Shafmaster Madge K.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	5,500	$0.00	$0.00
Grant/Award	Option (right to buy)	11,000	$0.00	$0.00

Holdings After Transaction: Option (right to buy) — 16,500 contracts (Direct)

Footnotes (2)

1. F1. The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.
2. F2. 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

Key Figures

Option grant size 1: 11,000 options Option grant size 2: 5,500 options Exercise price: $10.7700 per share +3 more

6 metrics

Option grant size 1 11,000 options Underlying 11,000 common shares granted on May 20, 2026

Option grant size 2 5,500 options Underlying 5,500 common shares granted on May 20, 2026

Exercise price $10.7700 per share Exercise price for both option grants

Expiration date May 20, 2036 Expiration for both options

Single-grant vesting date May 20, 2027 One option vests fully on this date, subject to service

Ratable vesting period 36 months Remaining shares on second option vest ratably over this period

Key Terms

Option (right to buy), exercise price, expiration date, vest in full, +1 more

5 terms

Option (right to buy) financial

"security_title: Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 10.7700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-05-20T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest in full financial

"The shares subject to this option shall vest in full on May 20, 2027"

vesting ratably financial

"remaining shares vesting ratably over thirty-six months"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ProMIS Neurosciences (PMN) report on this Form 4?

ProMIS Neurosciences reported that director Madge K. Shafmaster received two option awards. One covers 11,000 common shares and the other 5,500 shares, both with an exercise price of $10.7700 per share and an expiration date of May 20, 2036.

What are the exercise prices and terms of the new PMN director options?

The options granted to director Madge K. Shafmaster carry an exercise price of $10.7700 per share. Each option is a right to buy ProMIS Neurosciences common shares and expires on May 20, 2036, providing long-dated equity-based compensation exposure.

How do the new ProMIS Neurosciences options vest for director Madge K. Shafmaster?

One option grant vests in full on May 20, 2027, subject to continued Board service. The other vests 25% upon grant, with the remaining shares vesting ratably over thirty-six months, also subject to continued service on the Board of ProMIS Neurosciences.

How many ProMIS Neurosciences shares underlie the new options reported?

The Form 4 shows options over 11,000 underlying common shares in one grant and 5,500 underlying common shares in another. These derivative awards give the director the right to purchase those numbers of shares if the options are exercised in the future.

Are the ProMIS Neurosciences Form 4 transactions open-market buys or option grants?

The transactions are option grants, not open-market stock purchases. The Form 4 describes them as awards of options (rights to buy) common shares, with transaction code A indicating a grant, award, or other acquisition rather than a market buy or sell.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/22/2026 - 04:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shafmaster Madge K.

(Last) (First) (Middle)

C/O PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

(Street)

TORONTO M4S 3E2

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	$10.77	05/20/2026		A		5,500		(1)	05/20/2036	Common Shares	5,500	$0	5,500	D
Option (right to buy)	$10.77	05/20/2026		A		11,000		(2)	05/20/2036	Common Shares	11,000	$0	11,000	D

Explanation of Responses:

1. The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.

2. 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.

	/s/ Max Milbury, Attorney in Fact for Madge K. Shafmaster	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)